Form 4: Royalty Pharma EVP Acquires Indirect Beneficial Ownership of Class E Ordinary Shares

George W. Lloyd, EVP of Investments & CLO at Royalty Pharma plc, reports an indirect acquisition of 1,944,471 Class E ordinary shares through Royalty Pharma Holdings Ltd.

Summary

• George W. Lloyd, an Executive Vice President at Royalty Pharma plc, has reported changes in beneficial ownership.
• The report indicates an indirect acquisition of 1,944,471 Class E ordinary shares of Royalty Pharma Holdings Ltd (RPH).
• This acquisition is linked to the Membership Interests Purchase Agreement dated January 10, 2025.
• The Class E shares vest over a 9-year period and can be converted into Class B ordinary shares of RPH on a one-for-one basis.
• Class B shares can then be converted into Class A ordinary shares of Royalty Pharma plc, also on a one-for-one basis.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Future Outlook

The Class E shares will vest in installments over a 9-year period, implying a long-term incentive structure.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of shares by a key executive could be viewed positively by shareholders, aligning management's interests with theirs.

Key Dates

Keywords

Royalty Pharma, Beneficial Ownership, Class E Shares, George W. Lloyd, RPRX, Form 4, Acquisition, Investments, RPH, Conversion